BC
Birchview Capital Portfolio holdings
AUM
$101M
This Quarter Return
+1.1%
1 Year Return
+34.62%
3 Year Return
+103.2%
5 Year Return
+107.72%
10 Year Return
+352.1%
AUM
$101M
AUM Growth
+$101M
(-13%)
Cap. Flow
+$2.26M
Cap. Flow
% of AUM
2.25%
Top 10 Holdings %
Top 10 Hldgs %
56.77%
Holding
80
New
12
Increased
15
Reduced
13
Closed
9
Top Buys
| 1 |
KLA
KLAC
|
$14.2M |
| 2 |
Ovintiv
OVV
|
$2.1M |
| 3 |
NovoCure
NVCR
|
$1.25M |
| 4 |
Freeport-McMoran
FCX
|
$782K |
| 5 |
Structure Therapeutics
GPCR
|
$747K |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$16.7M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$1.63M |
| 3 |
United Therapeutics
UTHR
|
$934K |
| 4 |
Travere Therapeutics
TVTX
|
$518K |
| 5 |
Masimo
MASI
|
$505K |
Sector Composition
| 1 | Healthcare | 79.06% |
| 2 | Technology | 14.1% |
| 3 | Energy | 6.07% |
| 4 | Materials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Treace Medical Concepts
TMCI
$459M
| $1.04M | 1.03% |
176,947
+12,000
| +7% | +$70.6K |
|
27
Solid Biosciences
SLDB
$420M
| $871K | 0.86% |
178,768
+50,000
| +39% | +$244K |
|
28
Kiniksa Pharmaceuticals
KNSA
$2.52B
| $830K | 0.82% |
30,000
-6
| -0% | -$166 |
|
|
29
Freeport-McMoran
FCX
$64.3B
| $782K | 0.78% |
+18,033
| New | +$782K |
|
30
KalVista Pharmaceuticals
KALV
$706M
| $757K | 0.75% |
67,000
-2
| -0% | -$23 |
|
|
31
Structure Therapeutics
GPCR
$1.12B
| $747K | 0.74% |
+36,000
| New | +$747K |
|
32
Apogee Therapeutics
APGE
$2.24B
| $695K | 0.69% |
16,000
+8,000
| +100% | +$347K |
|
33
Outset Medical
OM
$241M
| $664K | 0.66% |
34,584
+10,000
| +41% | +$192K |
|
34
Xenon Pharmaceuticals
XENE
$2.99B
| $657K | 0.65% |
21,000
| – | – |
|
35
Ultragenyx Pharmaceutical
RARE
$3.03B
| $654K | 0.65% |
18,000
+2,000
| +13% | +$72.7K |
|
36
Axsome Therapeutics
AXSM
$6.15B
| $626K | 0.62% |
6,000
| – | – |
|
37
Olema Pharmaceuticals
OLMA
$409M
| $571K | 0.57% |
+134,000
| New | +$571K |
|
38
Scholar Rock
SRRK
$3.13B
| $567K | 0.56% |
16,000
| – | – |
|
39
Intellia Therapeutics
NTLA
$1.22B
| $563K | 0.56% |
+60,000
| New | +$563K |
|
40
OrthoPediatrics
KIDS
$524M
| $558K | 0.55% |
26,000
+6,000
| +30% | +$129K |
|
41
Immunome
IMNM
$819M
| $558K | 0.55% |
+60,000
| New | +$558K |
|
42
Xencor
XNCR
$605M
| $550K | 0.55% |
70,000
+44,000
| +169% | +$346K |
|
43
Halozyme
HALO
$8.61B
| $520K | 0.52% |
10,000
| – | – |
|
44
Pacific Biosciences
PACB
$378M
| $496K | 0.49% |
+400,000
| New | +$496K |
|
45
Inhibrx
INBX
$407M
| $458K | 0.46% |
32,110
| – | – |
|
46
MoonLake Immunotherapeutics
MLTX
$3.63B
| $378K | 0.38% |
8,000
| – | – |
|
47
Alphatec Holdings
ATEC
$2.31B
| $366K | 0.36% |
33,000
| – | – |
|
48
BioCryst Pharmaceuticals
BCRX
$1.74B
| $358K | 0.36% |
40,000
| – | – |
|
|
BPMC
49
DELISTED
Blueprint Medicines
BPMC
| $346K | 0.34% |
2,700
| – | – |
|
50
Cytokinetics
CYTK
$5.85B
| $330K | 0.33% |
10,000
| – | – |
|